Some research indicates that copper peptides may help support elastin-related processes and the maintenance of healthy connective tissue
Its theorized that interactions with dopaminergic and serotonergic pathways have also encouraged exploration into its possible impacts on neuro-gastrointestinal circuits
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
Armstrong JS, Whiteman M, Yang H, Jones DP, Sternberg Jr P
Injection protocols and timing Separate injections: Semaglutide: Subcutaneous, abdomen or thigh Cagrilintide: Subcutaneous, different site Same day, different locations Both weekly Timing considerations: Most take both same day (simplicity) Can split: Semaglutide Monday, Cagrilintide Thursday No evidence one timing superior Choose based on preference Injection technique: Standard subcutaneous injection 29-31 gauge needles Rotate injection sites No special requirements See our peptide injections guide , how to calculate peptide dosages , and how to reconstitute peptides if using research peptides